Genmab AS Aktie - GE9

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Current Price

205,80

Gebot

206,00

Fragen

206,10

Volumen

289

201,40 Tagesbereich 207,90

38,18 52-Wochen-Bereich 291,40

Marktkapitalisierung

13,519B

Handelsende

205,90

Handelsbeginn

203,00

Letzte Trade

205.8

Letzter Handelszeitpunkt

16:40:50

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

440

Ausgegebene Aktien

65.691.573

Dividendenrendite

Kurs-Gewinn-Verhältnis

3,11

Gewinn pro Aktie (EPS)

66,25

Erlöse

16,47B

Nettogewinn

4,35B

Sektor

Biological Pds,ex Diagnstics

Branche

Biogenetic (human)

Website

www.genmab.com

Hauptsitz

Copenhagen, Dnk

Gegründet

2000

Genmab AS is listed in the Biological Pds,ex Diagnstics sector of the Tradegate (DE) with ticker GE9. The last closing price for Genmab AS was 205,90 €. Over the last year, Genmab AS shares have traded in a share price range of 38,18 € to 291,40 €.

Genmab AS currently has 65.691.573 shares in issue. The market capitalisation of Genmab AS is 13,53 € billion. Genmab AS has a price to earnings ratio (PE ratio) of 3.11.

Notice to Convene the Annual General Meeting of Genmab A/S

Notice to Convene the Annual General Meeting of Genmab A/S Company Announcement Genmab A/S to hold Annual General Meeting on Wednesday March 12...

Genmab Files Annual Report with the U.S. Securities and Exchange Commission

Genmab Files Annual Report with the U.S. Securities and Exchange Commission Media ReleaseCOPENHAGEN, Denmark; February 12, 2025 Genmab filed Form...

Genmab Publishes 2024 Annual Report

Genmab Publishes 2024 Annual Report Company Announcement COPENHAGEN, Denmark; February 12, 2025 – Genmab A/S (Nasdaq: GMAB) announced today the...

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Grant of Restricted Stock Units and Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark; January 23, 2025 – Genmab A/S...

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024 Company Announcement Net sales of DARZALEX® in 2024 totaled USD 11,670...

Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference Media ReleaseCOPENHAGEN, Denmark; January 03, 2025Genmab A/S (Nasdaq: GMAB...

Genmab to Hold 2024 R&D Update and ASH Data Review Meeting

Genmab to Hold 2024 R&D Update and ASH Data Review Meeting Media Release Event to be held virtually via live webcast and archived on...

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination...

Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis

Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With...

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	23.6	12.9527991218	182.2	207.9	38.18	463	194.61063094	DE
4	5.2	2.59222333001	200.6	211.4	38.18	561	191.73191176	DE
12	9.25	4.70618163317	196.55	217.8	38.18	440	197.67565553	DE
26	-37.7	-15.4825462012	243.5	253.5	38.18	358	207.17454166	DE
52	-64.2	-23.7777777778	270	291.39999	38.18	269	224.0211417	DE
156	-77.2	-27.2791519435	283	362.9	38.18	212	235.8347042	DE
260	-167.8	-44.9143468951	373.6	374.3	38.18	189	236.29135959	DE

GE9 - Frequently Asked Questions (FAQ)

What is the current Genmab AS share price?

The current share price of Genmab AS is 205,80 €

How many Genmab AS shares are in issue?

Genmab AS has 65.691.573 shares in issue

What is the market cap of Genmab AS?

The market capitalisation of Genmab AS is EUR 13,53B

What is the 1 year trading range for Genmab AS share price?

Genmab AS has traded in the range of 38,18 € to 291,40 € during the past year

What is the PE ratio of Genmab AS?

The price to earnings ratio of Genmab AS is 3,11

What is the cash to sales ratio of Genmab AS?

The cash to sales ratio of Genmab AS is 0,82

What is the reporting currency for Genmab AS?

Genmab AS reports financial results in DKK

What is the latest annual turnover for Genmab AS?

The latest annual turnover of Genmab AS is DKK 16,47B

What is the latest annual profit for Genmab AS?

The latest annual profit of Genmab AS is DKK 4,35B

What is the registered address of Genmab AS?

The registered address for Genmab AS is KALVEBOD BRYGGE 43, COPENHAGEN, 1260

What is the Genmab AS website address?

The website address for Genmab AS is www.genmab.com

Which industry sector does Genmab AS operate in?

Genmab AS operates in the BIOGENETIC (HUMAN) sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
62UKWESST Micro Systems Inc	0,95 € (119,91%)	46,72k
7KOCullinan Metals Corp	0,013 € (58,54%)	55,84k
NL8Genesis Ai Corp	0,0328 € (43,86%)	1,47k
PA8Paion AG	0,027 € (37,76%)	24,39k
4APApollo Minerals Ltd	0,0155 € (34,78%)	18,7k
A07Avance Gas Holding Ltd	2,325 € (-56,54%)	133,54k
E3O1Nexoptic Technology Corp	0,0075 € (-51,61%)	456
W47Grid Battery Metals Inc	0,008 € (-40,74%)	6,1k
POTAPortofino Resources Inc	0,0028 € (-36,36%)	29,56k
D4GDataMetrex AI Ltd	0,0036 € (-28,00%)	50k
TKAThyssenkrupp AG	6,016 € (5,84%)	3,34M
PF8European Lithium Limited	0,0318 € (-5,92%)	3M
3CPXiaomi Corporation	5,902 € (6,67%)	2,25M
D7GNel ASA	0,2089 € (-0,05%)	2,23M
DMLSayona Mining Limited	0,015 € (6,38%)	1,19M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Genmab AS (GE9)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über Genmab AS

GE9 Neueste Nachrichten

Notice to Convene the Annual General Meeting of Genmab A/S

Genmab Files Annual Report with the U.S. Securities and Exchange Commission

Genmab Publishes 2024 Annual Report

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024

Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Genmab to Hold 2024 R&D Update and ASH Data Review Meeting

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

GE9 - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Genmab AS (GE9) Börsenkurse

Genmab AS (GE9)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über Genmab AS

GE9 Neueste Nachrichten

Notice to Convene the Annual General Meeting of Genmab A/S

Genmab Files Annual Report with the U.S. Securities and Exchange Commission

Genmab Publishes 2024 Annual Report

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024

Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Genmab to Hold 2024 R&D Update and ASH Data Review Meeting

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

GE9 - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen